Trial Profile
Non-interventional Study of the Safety and Efficacy of Long-term Somatropin Treatment in Children (GrowthWIN II / GrowthWIN II SGA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2015
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Acronyms GrowthWIN II; GrowthWIN II / GrowthWIN II SGA
- Sponsors Novo Nordisk
- 11 Apr 2015 New trial record